# wearable-device — high — Convergence Baseline

**Universe:** 140 Synthesize-group questions (Append-group convergence is not in scope per D1 — Append voices are preserved, not merged).
**Convergence groups:** 18
**Questions in convergence:** 95 of 140 (~68%)
**Convergence density:** 68%
**Unique (non-convergent) questions:** 45

**Convention:** A convergence group contains 2 or more questions from *different personas* addressing the same underlying concern. Within-persona repetition is not "convergence" and is handled via per-persona deduplication, not merge.

Each group is anchored to a B1 cluster. Merge recommendations are either:
- **Merge:** a single synthesized question that captures the shared concern; merge text is anchored in the source questions and persona attribution is preserved in a "drawn from" tag.
- **Preserve all distinct:** voices differ in framing or angle enough that a merge would lose meaningful content.

---

## Convergence Group 1 — On-Device Data Pipeline & PHI/Non-PHI Boundary

**Theme:** How the device pipeline delineates what constitutes "raw" vs "processed" data at each stage, what qualifies as PHI under HIPAA vs de-identified data, and the legal/technical architecture validating this before clinical partnerships.
**Cluster:** 1 (Privacy Architecture & Data Governance)
**Questions:**
- [Analyst Q5] HIPAA-compliant data segmentation framework — systematic approach determining "raw" vs "processed" at each pipeline stage; critical decision boundaries for transformation, aggregation, anonymization.
- [Analyst Q8] Companion app data sync architecture — privacy-preserving sync protocol for alerts and aggregated summaries; tradeoff between clinical-meaningful insights and re-identification risk.
- [DA Q4] HIPAA Paradox — ambiguity about what constitutes PHI vs de-identified data; how to architect the pipeline to clearly delineate; legal review validating architecture before clinical partnerships.
- [Lawyer Q4] De-identification standards — aggregated summaries cannot be reverse-engineered to identify individual health events; distinctive temporal patterns from arrhythmia detection.

**Merge recommendation: Merge.** Four-way convergence on the data-pipeline architecture and PHI/non-PHI boundary question.

**Merge text:** *What is the technical and legal architecture that delineates PHI from non-PHI in the on-device-to-companion-app pipeline — specifically the transformation, aggregation, and anonymization steps at each stage from raw sensor data through local inference through the privacy-preserving sync protocol, the formal legal review process that validates these boundaries before clinical partnerships are established, and the defense against re-identification from aggregated summaries and usage patterns (given the distinctive temporal fingerprints that rare but high-impact events like cardiac arrhythmia detection create)?* (drawn from Analyst, DA, Lawyer)

---

## Convergence Group 2 — Re-identification Risk & Third-Party Ecosystem

**Theme:** Whether combined processed alerts, aggregated summaries, and usage patterns can re-identify users across contexts, including through third-party APIs and platform integrations.
**Cluster:** 1
**Questions:**
- [Questioner Q3] Re-identification risks — combination of processed alerts, aggregated summaries, usage patterns creating unique fingerprint enabling user identification across platforms/contexts.
- [Questioner Q4] Third-party ecosystem — companion app architecture and APIs preventing third-party integrations (health platforms, insurance partners) from indirectly reconstructing sensitive data.
- [TE Q10] Privacy-preserving telemetry architecture — minimally hashed diagnostic payloads, opt-in crisis dump telemetry, differential noise injection for aggregate metrics; actionable data while preserving privacy.

**Merge recommendation: Merge.** Three-way convergence on the re-identification-risk / third-party-exposure question.

**Merge text:** *What are the re-identification risks from the combination of processed alerts, aggregated summaries, and usage patterns — whether the unique temporal fingerprint of rare events can be reconstructed across platforms or contexts, whether third-party integrations (health platforms, insurance partners, research platforms) can indirectly reconstruct the sensitive data the on-device commitment is meant to protect, and what technical architecture (minimally hashed diagnostic payloads, opt-in crisis dump telemetry, differential-privacy noise injection, API-level safeguards) allows actionable telemetry and ecosystem participation without re-identification?* (drawn from Questioner, TE)

---

## Convergence Group 3 — Privacy as Felt User Trust vs Compliance Checklist

**Theme:** Whether users viscerally feel their data is safe — the experiential translation of on-device architecture into communicated trust, as distinct from meeting legal/technical requirements.
**Cluster:** 1
**Questions:**
- [AI Q2] When privacy creates trust and openness — safety palpable in a context (therapist, journal); designing device so users feel that depth from day one.
- [AI Q8] Privacy architecture as user experience, not compliance — interface design, communication patterns, transparency making privacy feel viscerally real.
- [DA Q9] Privacy Paradox Perception — users may not understand why on-device matters; communicating to non-technical users; transparency features building trust.
- [Empath Q4] Privacy as a feeling, not a feature — visceral difference between "data stays on device" vs "encrypted and secure"; physical containment and relationship with self-monitoring.
- [Futurist Q5] Consumer privacy expectations trajectory — public concern growing measurably; operationalizing "data minimization" as core value proposition rather than technical constraint.

**Merge recommendation: Merge.** Five-way convergence on the privacy-as-felt-trust question with compatible framings across AI (appreciative), DA (critical), Empath (experiential), Futurist (trend), and the shared concern that technical on-device architecture does not automatically produce user-felt trust.

**Merge text:** *How does the privacy architecture translate from technical guarantee into user-felt trust — specifically communicating on-device processing to non-technical users in a way they viscerally feel (not merely understand intellectually), designing the interface and transparency mechanisms so physical data containment produces the same depth of trust users experience in therapist/journal-type contexts, addressing the paradox where the companion-app sync may be perceived as a privacy violation regardless of technical safeguards, and operationalizing "data minimization" as a market-facing value proposition as consumer privacy expectations continue to rise?* (drawn from AI, DA, Empath, Futurist)

---

## Convergence Group 4 — Jurisdictional Compliance & State-Level Health Data Laws

**Theme:** How the device complies with the patchwork of state-level consumer health data laws (CMIA, My Health My Data Act) and international data residency requirements that extend beyond HIPAA.
**Cluster:** 1
**Questions:**
- [Lawyer Q3] State-level medical data regulations — California CMIA, Washington MHMDA apply regardless of covered-entity status; which states as baseline given nationwide distribution.
- [Lawyer Q6] Data subject rights implementation — GDPR/CCPA access, deletion, portability; technical mechanisms without cloud storage dependencies.
- [Futurist Q4] Data sovereignty requirements acceleration — international residency/localization laws; on-device positioning vs cloud-dependent competitors; geographic markets.
- [Futurist Q6] HIPAA evolution and beyond — floor vs ceiling; state patchwork creating stricter requirements; compliance portability without product fragmentation.

**Merge recommendation: Merge.** Four-way convergence on the jurisdictional patchwork question.

**Merge text:** *How does the device architecture achieve compliance portability across the growing patchwork of state-level health-data laws (California CMIA, Washington My Health My Data Act, and forthcoming state frameworks) and international data residency requirements (GDPR/CCPA access, deletion, portability; EU data sovereignty; forthcoming jurisdictions) — treating HIPAA as a floor rather than a ceiling, implementing technical mechanisms for user rights (export, erasure) without creating cloud-storage dependencies that contradict the on-device commitment, and determining which geographic markets become most attractive for an on-device-only architecture vs cloud-dependent competitors?* (drawn from Lawyer, Futurist)

---

## Convergence Group 5 — Wellness/Clinical Classification Boundary & Architectural Path Dependency

**Theme:** The specific boundary between "wellness" and "medical device" regulatory classification, how marketing/UI/claims can cross it, and what architectural decisions now preserve FDA 510(k) optionality without prematurely committing.
**Cluster:** 2 (Wellness-to-Clinical Pathway)
**Questions:**
- [Analyst Q9] Consumer wellness to clinical device migration pathway — phased approach enabling smooth transition; architectural decisions creating technical debt vs regulatory acceleration.
- [Analyst Q10] Regulatory strategy decision tree — FDA clearance from day one vs wellness first; opportunity cost of delayed market entry vs clinical partnerships from clearance.
- [DA Q2] Wellness-to-Clinical Gap — users treating wellness alerts as medical diagnoses; product/marketing/legal safeguards; 18-month runway impact of dual-path; additional clinical studies for FDA clearance.
- [Lawyer Q1] Wellness vs medical device boundary — marketing materials/UI/documentation could cross into "diagnosis" or "treatment"; compliance-by-design guardrails preserving flexibility.
- [Systems Thinker Q6] Regulatory strategy path dependency — consumer-grade data collection not meeting clinical evidence requirements; minimal architectural decisions now to avoid rebuilding; "regulatory optionality."
- [FPT Q7] Wellness vs clinical at technical level — measurable thresholds separating wellness from medical device; architected from day one to demonstrate those criteria.
- [Futurist Q1] Regulatory convergence window — FDA expanding SaMD and AI/ML framework; architecting today to make future 510(k) straightforward without over-constraining.
- [AI Q6] Regulatory success as enabler — FDA process as collaboration making device demonstrably more valuable; clinical partnerships enhancing rather than restricting.

**Merge recommendation: Merge.** Eight-way convergence — the heaviest cross-persona group in this cell — on the wellness/clinical boundary and architectural-path-dependency question.

**Merge text:** *What is the specific wellness/clinical classification boundary and how do today's architectural, data-collection, and marketing decisions preserve FDA 510(k) optionality without prematurely committing — concretely identifying where marketing materials, UI language, and documentation risk crossing from "wellness" into "diagnosis" or "treatment" claims that would trigger medical-device classification, deciding between pursuing FDA clearance from day one vs launching as a wellness device and retrofitting clinical-grade processes later (including the opportunity cost of delayed market entry vs the competitive advantage and clinical partnerships that clearance enables), and identifying the minimal set of architectural-and-data-collection decisions to make now (design controls, evidence-generation capability, demonstrable measurable thresholds of clinical validity) that create "regulatory optionality" rather than either premature clinical burden or an irreversible consumer-wellness commitment — all while treating the FDA process as a collaboration that makes the device demonstrably more valuable to users rather than as an obstacle?* (drawn from Analyst, DA, Lawyer, Systems Thinker, FPT, Futurist, AI)

---

## Convergence Group 6 — Pre-Submission QMS & Clinical Evidence Generation

**Theme:** Prudent quality-management and clinical-validation activities to document now that accelerate eventual 510(k) submission, proportionate to a 12-person startup.
**Cluster:** 2
**Questions:**
- [Analyst Q11] Clinical evidence requirements analysis — structured breakdown of evidence generation for consumer wellness and 510(k); analytical validation transitioning to clinical validation; resource allocation impact.
- [Lawyer Q2] Pre-submission strategy — QMS records, design history files, software validation protocols; prudent practices even if clinical pathway never materializes.
- [Lawyer Q10] QMS scale for 12-person startup — design controls, supplier qualification, CAPA, complaint handling proportionate to startup; quality records accelerating 510(k) prospective vs reconstructed.
- [Analyst Q14] Per-unit cost of regulatory compliance — HIPAA infrastructure, FDA preparation, ongoing regulatory maintenance; fixed vs variable; production volume where material to unit economics.

**Merge recommendation: Merge.** Four-way convergence on the pre-submission/QMS scaling question.

**Merge text:** *What pre-submission quality-system and clinical-evidence activities should the 12-person team document prospectively to accelerate an eventual 510(k) while remaining proportionate to startup scale — specifically a structured breakdown of evidence generation for both consumer-wellness positioning and future clinical submission (including the transition point from analytical validation to clinical validation and resource-allocation impact), the QMS elements to implement now (design controls, supplier qualification, CAPA, complaint handling, design history files, software validation) versus reconstruct later, and the per-unit cost analysis of HIPAA infrastructure and FDA pathway preparation showing which costs are fixed versus variable and at what production volume they become materially significant to unit economics?* (drawn from Analyst, Lawyer)

---

## Convergence Group 7 — Clinical Integration & Reimbursement Trajectory

**Theme:** Healthcare-system adoption of remote patient monitoring and chronic-care-management reimbursement; payer coverage for preventive monitoring; positioning for hospital partnerships within 2-3 years.
**Cluster:** 2
**Questions:**
- [Futurist Q2] Clinical integration trajectory — RPM/CCM reimbursement codes accelerating; data export capabilities and integration hooks for hospital partnerships within 2-3 years.
- [Futurist Q10] Consumer-grade clinical convergence — gap narrowing; risk of awkward middle ground.
- [Futurist Q11] Payer coverage expansion trajectory — coverage for preventive monitoring expanding, particularly cardiovascular; evidence generation positioning for coverage decisions.
- [AI Q10] From wellness to clinical: learning across the boundary — wellness and clinical path as continuum; what wellness could learn from clinical standards; cross-borrowing making each stronger.

**Merge recommendation: Merge.** Four-way convergence on the clinical-integration-and-reimbursement trajectory.

**Merge text:** *How does the device position for the convergence of consumer-wellness and clinical-grade monitoring within a 2-3 year horizon — specifically what data export capabilities and integration hooks to build now for hospital partnerships (given accelerating RPM/CCM reimbursement codes), what evidence-generation investments position for expanding payer coverage decisions (particularly in cardiovascular preventive monitoring), how to avoid being caught in an "awkward middle ground" as consumer-grade and clinical-grade continue to converge, and what mutual learning across the wellness/clinical boundary (clinical-validation standards improving the wellness experience; wellness UX insights improving clinical usability) strengthens both paths without requiring a hard migration?* (drawn from Futurist, AI)

---

## Convergence Group 8 — Wellness/Clinical User Interpretation & Journey

**Theme:** How users interpret "wellness" vs "clinical" framing, especially as clinical-sounding language (arrhythmias, sleep apnea) is used in wellness context, and how users transition from wellness use to clinical advocacy when they develop actual symptoms.
**Cluster:** 2 (also touches 4)
**Questions:**
- [AA Q3] How different populations interpret "wellness device" vs "clinical device" when making health decisions — clinical-sounding language; users acting on alerts as medical diagnoses.
- [AA Q13] Transition when users develop actual health concerns — user starts for wellness, experiences real symptoms, tries to advocate in healthcare system; data-vs-clinical-needs gap.
- [Empath Q12] Transition from wellness to medical — emotional relationship change when device shifts from "helping stay healthy" to "diagnosing"; psychological cost when company announces FDA pursuit.

**Merge recommendation: Preserve all distinct.** AA Q3 frames as stakeholder-interpretation (legal, ethical, experiential cross-population concern); AA Q13 frames as journey-mapping (wellness→symptom→clinical-advocacy gap); Empath Q12 frames as felt-experience (emotional relationship to device changing). Three distinct framings with distinct tactical implications — AA Q3 suggests UI language discipline; AA Q13 suggests data-export and clinical-translation design; Empath Q12 suggests communication strategy around company-level pivots. Merging collapses the stakeholder/journey/felt-experience trichotomy.

---

## Convergence Group 9 — Model Architecture, Quantization & NPU Utilization

**Theme:** Selecting model architectures (CNNs vs transformers) and quantization strategies that maximize NPU utilization within thermal and power constraints while meeting clinical-grade detection accuracy.
**Cluster:** 3 (ML Architecture & NPU)
**Questions:**
- [Analyst Q1] Model architecture decision framework — model complexity, inference frequency, quantization tradeoffs; CNNs for PPG vs transformer-based temporal; detection accuracy vs power.
- [Analyst Q4] Inference latency vs accuracy tradeoff curve — acceptable latency window for real-time cardiac arrhythmia detection; how constraint shapes architecture choices.
- [DA Q8] Compute-Accuracy Tradeoff — low-power MCU+NPU constraints on model complexity; specific accuracy thresholds; validation that power hasn't forced unacceptable compromises.
- [Questioner Q17] NPU utilization limits — percentage of theoretical capacity sustainable given thermal constraints; user experience when throttling.
- [TE Q1] Model quantization and architecture selection — asymmetric model architectures where sleep analysis uses simpler model than cardiac event detection.
- [TE Q2] NPU utilization — INT8 acceleration, sparse compute, zero-point quantization; fallback paths for firmware updates improving model accuracy.
- [FPT Q6] NPU assumption — is matrix multiplication the bottleneck; traditional ML or statistical signal processing with equivalent clinical utility at less power.

**Merge recommendation: Merge.** Seven-way convergence on the model-architecture/NPU-utilization question.

**Merge text:** *How does the model architecture, quantization strategy, and NPU utilization plan meet real-time clinical-grade detection accuracy (for arrhythmias and sleep apnea) within thermal and power constraints — specifically evaluating CNNs for PPG signal processing versus transformer-based approaches for temporal pattern recognition, asymmetric architectures where different event types (cardiac vs sleep) use different model complexity, the specific NPU features to leverage (INT8 acceleration, sparse compute, zero-point quantization), the percentage of theoretical NPU capacity sustainable under thermal constraints and the user-experience consequences of throttling, the latency/accuracy tradeoff curve for sub-5-second cardiac response, the specific accuracy thresholds being targeted for each event type with validation that power constraints have not forced unacceptable compromises, and the first-principles question of whether a carefully-optimized traditional ML pipeline or hand-crafted signal processing could achieve equivalent clinical utility at orders of magnitude less power (i.e., whether matrix multiplication is actually the bottleneck)?* (drawn from Analyst, DA, Questioner, TE, FPT)

---

## Convergence Group 10 — Model Updates, Drift & Personalization Deployment

**Theme:** How models are updated in production, how drift is detected and corrected, how on-device personalization is preserved across firmware rollouts, and whether federated learning is viable given hardware and communication constraints.
**Cluster:** 3 (also touches 8)
**Questions:**
- [Analyst Q6] On-device learning strategy evaluation — incremental vs federated vs firmware updates; regulatory, UX, complexity, maintenance matrix.
- [DA Q6] Model Drift Without Retraining — drift from sensor degradation, user physiology, firmware updates, population shifts; monitoring infrastructure; update frequency for clinical-grade accuracy.
- [Questioner Q9] Model update strategy — firmware-delivered improvements while preserving personalized adaptations; transition without disrupting user trust.
- [Questioner Q10] Federated learning feasibility — realistic conditions given user-base heterogeneity, hardware constraints, communication costs; alternative paths to model improvement.
- [Systems Thinker Q7] Model update sync-asynchrony problem — multiple model versions in the wild; attribution of detection changes; phased rollouts, embedded versioning, A/B test infrastructure.
- [Futurist Q7] Edge ML capability trajectory — NPU and inference engines improving at documented pace; architecture and update mechanisms taking advantage of 2-3 generations of hardware without device replacement.
- [Futurist Q8] Federated learning infrastructure timing — federated frameworks maturing; architectural flexibility now to support within 18-24 months vs committing to periodic firmware updates.

**Merge recommendation: Merge.** Seven-way convergence on the model-update / drift / personalization-deployment question.

**Merge text:** *What is the model-update, drift-detection, and personalization-deployment strategy across the device's multi-year lifecycle — specifically evaluating the tradeoffs among on-device incremental learning, federated learning (under what realistic conditions it would actually work given user-base heterogeneity, 128KB-class SRAM hardware constraints, and communication costs), and periodic firmware updates across regulatory, user-experience, technical-complexity, and ongoing-maintenance dimensions; how production model drift (from sensor degradation, user-physiology change, firmware update, population distribution shift) is detected and corrected with the right monitoring infrastructure and update cadence for clinical-grade accuracy; how personalized on-device adaptations are preserved across firmware rollouts without disrupting user trust; how the asynchronous-deployment problem (multiple model versions in the wild making attribution of detection-quality changes difficult) is handled through phased rollouts, embedded model versioning in alert data, and A/B test infrastructure compatible with firmware constraints; and whether to invest architectural flexibility now for federated learning within 18-24 months given documented edge-ML capability trajectory, or commit to periodic firmware updates and capture 2-3 generations of hardware improvement through the update path?* (drawn from Analyst, DA, Questioner, Systems Thinker, Futurist)

---

## Convergence Group 11 — NPU Vendor Lock-in & Hardware-Software Iteration Cadence

**Theme:** Vendor dependency on the chosen NPU and the mismatch between 18-month hardware cycles and weekly software updates; multi-vendor strategy and architectural leverage points.
**Cluster:** 3
**Questions:**
- [DA Q7] NPU Lock-in Risk — vendor dependency limiting model architecture flexibility; vendor discontinuation, price increases, technology stagnation; multi-vendor strategies for optionality.
- [Questioner Q20] Hardware-software iteration cadence — 18-month hardware vs weekly software; leveraging future silicon without designing into corner requiring expensive respins.

**Merge recommendation: Merge.** Two-way convergence on the vendor-dependency / iteration-cadence question.

**Merge text:** *What is the strategy for managing NPU vendor dependency and the mismatch between 18-month hardware iteration cycles and weekly software update capability — specifically how to architect the ML pipeline to take advantage of future silicon capabilities that may not exist in the initial NPU without designing into a corner that requires expensive respins, what architectural alternatives or multi-vendor strategies preserve optionality if the chosen NPU vendor discontinues the chip, raises prices, or fails to advance the technology, and where the leverage points exist to decouple model-architecture decisions from specific vendor features?* (drawn from DA, Questioner)

---

## Convergence Group 12 — Sensor Fusion Architecture, Quality & Graceful Degradation

**Theme:** Combining asynchronous multi-modal sensor data, validating signal quality to prevent false positives from corrupted inputs, and designing graceful degradation when individual sensors fail.
**Cluster:** 6 (Sensor Fusion & Signal Quality)
**Questions:**
- [Analyst Q2] Sensor fusion strategy for multi-modal anomaly detection — early vs late fusion; framework; computational cost vs marginal improvement in sensitivity.
- [Questioner Q8] Sensor failure graceful degradation — PPG contact issues with skin tone/tattoos; pipeline gracefully degrading rather than producing unreliable outputs.
- [Questioner Q18] Sensor fusion complexity — combining asynchronous inputs; marginal benefit of additional inputs vs computational/calibration costs.
- [Systems Thinker Q11] Sensor fusion interdependence fragility — PPG becomes unreliable → model over-weights remaining sensors producing false confidence; artificial sensor dropout training, explicit confidence per sensor, single-sensor fallback.
- [TE Q4] Multi-modal sensor fusion architecture — asynchronous inputs (PPG 50Hz, accelerometer 25Hz, temperature 1Hz, mic 100Hz) while maintaining causality; early/late/hybrid attention gating.
- [TE Q5] Signal quality validation — motion artifact detection, PPG perfusion, sensor fault detection gating inference inputs; power budget impact.

**Merge recommendation: Merge.** Six-way convergence on the sensor-fusion architecture / graceful-degradation question.

**Merge text:** *What is the sensor-fusion architecture that combines asynchronous multi-modal inputs (PPG at 50Hz, accelerometer at 25Hz, skin temperature at 1Hz, microphone 100Hz bursts) while maintaining causality for real-time alerts — specifically the decision among early fusion (at the raw-signal level), late fusion (at per-sensor feature extraction and decision level), and hybrid architectures with attention gating; the point at which marginal sensor additions fail to justify computational and calibration costs; the real-time signal-quality validation (motion-artifact detection, PPG perfusion validation, sensor-fault detection) that gates inference inputs, and the power-budget cost of those quality checks; and crucially the graceful-degradation behavior when one sensor becomes unreliable (PPG contact issues with skin tone or tattoos, accelerometer saturation, microphone obstruction) — training with artificial sensor dropout so the fusion architecture does not over-weight remaining sensors and produce false confidence, modeling explicit confidence per sensor, and providing single-sensor fallback modes rather than catastrophic failure?* (drawn from Analyst, Questioner, Systems Thinker, TE)

---

## Convergence Group 13 — Alert Threshold Calibration & False-Positive/Fatigue Dynamics

**Theme:** Balancing sensitivity and specificity in alert generation across stakeholder definitions (user peace of mind, clinical diagnostic utility, manufacturer liability), with attention to alert-fatigue dynamics and the cry-wolf failure mode.
**Cluster:** 4 (Alert Design)
**Questions:**
- [Analyst Q7] False positive/false negative calibration protocol — systematic threshold determination; quantifying missed detection costs vs unnecessary anxiety and alert fatigue; evidence-based thresholds.
- [DA Q1] False Positive Burden — anxious 40+ target; frequent false positives creating stress and medical-system strain; sensitivity vs alert fatigue vs missed-true-positive liability.
- [Questioner Q13] Alert threshold ethics — "optimal" meaning different things to users, clinicians, and company; liability and alarm-fatigue balance.
- [Systems Thinker Q1] Alert fatigue calibration loop — false positives → trust erosion → notifications disabled → no protective benefit; "better safe than sorry" vs "boy who cried wolf"; individual and temporal tolerance variation.
- [Futurist Q12] Alert fatigue and retention dynamics — documented decline in engagement with notification-based interventions; alert strategy without contributing to notification burnout.

**Merge recommendation: Merge.** Five-way convergence on the alert-calibration/fatigue question.

**Merge text:** *How is the alert-threshold calibration system designed to navigate the sensitivity/specificity balance when "optimal" means different things to different stakeholders — users wanting peace of mind, clinicians wanting diagnostic utility, and the company wanting to avoid liability and alarm fatigue — with evidence-based thresholds derived from systematic quantification of the costs of missed detection versus unnecessary anxiety and medical-system strain, explicit attention to the alert-fatigue feedback loop (false positives → trust erosion → notifications disabled or device removed → no protective benefit, versus thresholds set too high to avoid this and missing genuine events), the documented decline in engagement with notification-based interventions over time, and the cry-wolf failure mode on a 40+ cardiac-concerned population where liability asymmetry pushes toward sensitivity but user retention pushes toward specificity — including how individual and temporal variation in alert tolerance is accommodated without destabilizing the calibration?* (drawn from Analyst, DA, Questioner, Systems Thinker, Futurist)

---

## Convergence Group 14 — Alert Comprehension, Actionability & User Agency

**Theme:** What users experience when receiving alerts they cannot verify or challenge, how alerts connect to actionable intervention, and the social/professional friction when alerts fire in sensitive contexts.
**Cluster:** 4
**Questions:**
- [AA Q1] User perception of alerts from device they don't fully understand — emotional journey when alert arrives about cardiac anomaly; privacy-transparency balance affecting trust.
- [AA Q2] Users discovering the device makes mistakes but can't access raw data — false positive during job interview/wedding/sleep; agency and trust when device gets it wrong.
- [AA Q9] Power dynamics when users receive alerts they can't verify or challenge — bodily autonomy and relationship with own signals.
- [DA Q12] Alert Actionability Gap — detection without connecting to treatment/intervention pathways; ensuring alerts lead to meaningful action; partnerships closing detection-to-care loop.
- [Empath Q3] False alarms and emotional whiplash — 3 AM adrenaline spike, scramble to verify, lingering aftermath; cry-wolf dynamic.
- [Empath Q9] The promise that can't be kept — inevitable misses; designing expectations that don't set users up for betrayal.

**Merge recommendation: Preserve all distinct.** Six distinct angles — AA Q1 (alert comprehension with limited transparency), AA Q2 (trust recovery after false positive in sensitive context), AA Q9 (bodily autonomy under unverifiable alerts), DA Q12 (actionability/intervention pathway), Empath Q3 (immediate emotional whiplash), Empath Q9 (long-run miss expectation-setting). Each addresses a different dimension of the same core concern. Merging would collapse this into a generic "design alert UX for trust" question that loses the distinct tactical implications of each framing.

---

## Convergence Group 15 — Continuous-Monitoring Psychological Burden & Health Anxiety

**Theme:** The self-amplifying pattern where continuous monitoring increases awareness of normal variation, which users interpret as problems, creating monitoring/anxiety feedback. Spans explicit systems-archetype framing and felt-experience framings.
**Cluster:** 5 (User Experience & Hyper-Vigilance)
**Questions:**
- [AA Q10] Users' relationship evolving — hyper-vigilance vs alert fatigue; anxiety during charging gaps; sustained healthy engagement without anxiety or dependency.
- [AA Q12] Body image and health anxiety over months — hyper-awareness of physiological signals; effects on users with pre-existing health anxiety.
- [Empath Q1] Living under constant watch — constant background vigilance affecting ease and trust in own health.
- [Empath Q5] When technology becomes the authority — trusting the machine over own sensations; reshaping relationship with body signals.
- [Empath Q6] The anxiety of optimization — obsession with micro-fluctuations; hypervigilance masquerading as empowerment.
- [Systems Thinker Q2] Health anxiety reinforcement cycle — more data visibility → more attention to fluctuations → more anxiety → more checking; normalizing variation, framing uncertainty, smoothing displays.
- [Systems Thinker Q3] Behavioral adaptation shadow system — observer effect; users sleeping differently knowing they're tracked; adaptation differing across adopter segments.

**Merge recommendation: Preserve all distinct.** Seven distinct framings — AA structural (stakeholder journey across time), Empath felt-experience (how it feels from the inside), Systems Thinker archetypal (named reinforcing/shadow loops). AA Q10 is a time-evolution framing; AA Q12 is a demographic-sensitivity framing; Empath Q1/Q5/Q6 are phenomenological vignettes (constant watch, authority-shift, optimization-anxiety); ST Q2 is a named reinforcing-loop archetype; ST Q3 is the observer-effect archetype. Each implies different tactical interventions — AA → design patterns for sustained healthy engagement; Empath → felt-experience design language; ST → explicit archetype-breaking design elements (variation normalization, display smoothing, opt-out of own data). Merging into one "address continuous-monitoring anxiety" question strips the decomposition that makes these different design concerns.

---

## Convergence Group 16 — 7-Day Battery Target Feasibility & Power Budget

**Theme:** Whether the 7-day battery life is realistic given continuous sensing + on-device ML inference + display + BLE, and the power-budget decomposition across subsystems.
**Cluster:** 7 (Power Budget)
**Questions:**
- [Analyst Q3] Power budget allocation methodology — systematic 7-day breakdown across sensing/inference/display/communication; maximum inference energy per cycle; highest-leverage sensitivity.
- [DA Q5] Battery Reality Check — 7-day life with continuous multi-sensor + ML + display + BLE as aggressive target for wrist form factor; specific power budget modeled; contingency if NPU/sensors consume more than lab specs.
- [Questioner Q16] 7-day battery reality check — assumptions about charging frequency, display usage, BLE sync embedded in target; real-world patterns dramatically different.
- [FPT Q4] What does 7 days actually buy us — first-principles argument for 7 specifically; designing from user behavior (nightly routines, weekly sync habits) vs round numbers.
- [FPT Q5] Invert the power budget paradigm — power as primary constraint; "we have X milliwatts continuous — what is maximum clinical value" vs fitting features into budget.
- [TE Q7] Battery budget decomposition — sub-5mW average power for 7 days across sensing/compute/storage/communication; technical leverage points.

**Merge recommendation: Merge.** Six-way convergence on the 7-day feasibility / power-budget decomposition question.

**Merge text:** *What is the defensible power-budget decomposition across the 7-day battery target, and is that target realistic given the continuous sensing + on-device ML inference + display + BLE load on a wrist form factor — specifically the sub-5mW average power-draw allocation across sensing subsystems (PPG driver, accelerometer, mic, BLE), compute (NPU vs MCU cores), storage (flash writes for event logs), and communication (BLE advertising vs connection events), the maximum inference energy budget per analysis cycle, the technical leverage points for optimization, the contingency plan if real-world NPU/sensor consumption exceeds lab specifications, the real-world-usage assumptions embedded in the 7-day target (charging frequency, display usage, BLE sync frequency) and what happens if those assumptions are violated — and the first-principles reframing of whether "7 days" is even the right target (derivable from user behavior patterns like nightly routines or weekly sync habits rather than a round number) and whether the entire design should invert the budget paradigm to "we have X continuous milliwatts — what is the maximum clinical value we can deliver" rather than "we need these features — how do we fit into X milliwatts"?* (drawn from Analyst, DA, Questioner, FPT, TE)

---

## Convergence Group 17 — Battery Degradation & Charging Gap Dynamics

**Theme:** The 15-25% battery-capacity degradation over 2-3 year lifetime forcing capability drift, weekly charging creating monitoring gaps, and the graceful-degradation approach that preserves core capability.
**Cluster:** 7
**Questions:**
- [DA Q10] Charging Disruption — weekly charging creating monitoring gaps; user education; hot-swappable batteries or alternative approaches.
- [Systems Thinker Q8] Battery-degraded capability drift — 15-25% capacity loss forcing throttling; marketing promised 7 days; hardware decisions shaping years-later user experience; graceful degradation vs sudden capability loss.
- [Futurist Q9] Battery technology constraints — energy density slowing relative to computational demands; graceful degradation preserving core detection when power margins tighten.

**Merge recommendation: Merge.** Three-way convergence on the degradation-and-charging-gap question.

**Merge text:** *How does the device handle the combined problem of weekly-charging monitoring gaps and multi-year battery-capacity degradation — specifically the charging-window data-collection gaps (potentially missing events during the charging period), user-education for minimizing monitoring disruption and consideration of hot-swappable or alternative charging approaches, and the delayed consequence where early hardware decisions (battery sizing, power-management architecture) shape user experience 2-3 years later when battery degrades 15-25% and the marketed "7 days" drops to 4-5 — including the power-management system, adaptive-sampling, and model-architecture design choices that produce graceful degradation rather than sudden capability loss, especially as energy-density improvements continue to slow relative to computational demands?* (drawn from DA, Systems Thinker, Futurist)

---

## Convergence Group 18 — Clinical Validation, Evidence & Primitive Reframing

**Theme:** Whether anomaly-detection-from-baseline is the correct ML primitive (vs pattern-recognition for known pathological signatures), how to establish clinical validity without labeled clinical data, and the self-selection bias in clinical validation studies relative to eventual mainstream users.
**Cluster:** 8 (Personalization, Validation & Clinical Evidence)
**Questions:**
- [Questioner Q12] Gold standard data acquisition — without labeled clinical data, establishing that detection catches claimed conditions vs noise or correlated patterns.
- [Systems Thinker Q9] Clinical validation self-selection bias — motivated study participants differ from mainstream; potential "Fixes that Fail"; stratifying study, weighting training, modeling concerned-vs-casual users.
- [FPT Q3] Is anomaly detection the right primitive — dangerous state IS patient's normal for many cardiac/respiratory conditions; pattern recognition for known pathological signatures vs deviation from baseline.
- [FPT Q8] Are we solving the right clinical problem for the right user — continuous monitoring creating net positive outcomes; "maximize clinically-meaningful interventions per unit user anxiety" vs "maximize detection sensitivity."

**Merge recommendation: Preserve all distinct.** Four distinct first-principles / validation-methodology framings. Questioner Q12 (data-acquisition methodology), ST Q9 (study-population-bias archetype), FPT Q3 (ML-primitive reframing), FPT Q8 (problem-formulation reframing). Merging collapses the distinction between validation-methodology concerns and ML-primitive reframing — two genuinely different research directions. Keep all four; they anchor the cluster's reductive-analytical signature.

---

## Unique (Non-Convergent) Questions

**Count:** 45 of 140 (~32%)

These questions express distinctive concerns that no other Synthesize persona articulates. They should survive synthesis verbatim or with only light editing — their unique-territory status means merging them would lose content rather than consolidate it.

Listed by persona for B3 reference (full text in test-data file):

**Analyst (3 unique):** Analyst has 15 questions. Appearing in CGs: Q1→CG-9, Q2→CG-12, Q3→CG-16, Q4→CG-9, Q5→CG-1, Q6→CG-10, Q7→CG-13, Q8→CG-1, Q9→CG-5, Q10→CG-5, Q11→CG-6, Q14→CG-6. Not in CG: Q12 (BOM optimization), Q13 (runway allocation), Q15 (ML resource allocation between accuracy and efficiency). **Analyst unique: 3 of 15 (Q12, Q13, Q15).**
*Analyst contributes 12 of 15 questions to convergence groups — high-convergence persona in this cell. Unique contributions are business-operational (BOM, runway, team-allocation) — the Cluster 10 business-concerns that are Analyst-only at the strategic-quantitative level.*

**Appreciative Inquirer (7 unique):** AI has 12 questions. Appearing in CGs: Q2→CG-3, Q6→CG-5, Q8→CG-3, Q10→CG-7. Not in CG: Q1 (peak health awareness moments), Q3 (invisible partner technology), Q4 (three years later celebration), Q5 (no-false-alarm experience), Q7 (12-engineer team cross-functional excellence), Q9 (battery as invitation, not constraint), Q11 (smallest meaningful experiment), Q12 (existing assets we haven't fully leveraged). **AI unique: 8 of 12 (Q1, Q3, Q4, Q5, Q7, Q9, Q11, Q12).**
*High unique rate (~67%). Consistent with AI's strengths-based framing being orthogonal to deficit-framed convergence. AI contributes to Cluster 5 (Q1, Q3, Q4), Cluster 4 (Q5), Cluster 7 (Q9), Cluster 10 (Q7, Q11, Q12). AI's voice is at structural risk of being dropped wholesale if synthesis prioritizes deficit-framed convergence content. Q5 (no-false-alarm) and Q9 (battery as invitation) are especially at risk because their clusters are otherwise deficit-framed.*

**Audience Advocate (3 unique):** AA has 13 questions. Appearing in CGs: Q1→CG-14 (preserve-distinct), Q2→CG-14, Q9→CG-14, Q10→CG-15 (preserve-distinct), Q12→CG-15. In B1 orphans: Q3, Q7, Q8, Q13 (multi-cluster bridges). Not in CG and not orphan: Q4 (training data distribution — Cluster 11), Q5 (disabilities — Cluster 11), Q6 (battery routines — Cluster 11), Q11 (false positives in social contexts — Cluster 4). Wait — Q11 is in Cluster 4 but not explicitly listed in CG-14. Checking: AA Q11 is about false-positive social/professional friction; this is distinct from the alert-UX concerns in CG-14 and clusters better with AA Q9/Empath Q3 style. Including in Cluster 4 but no cross-persona convergence — unique. **AA unique: 4 of 13 (Q4, Q5, Q6, Q11).**
*AA's unique voice is concentrated in Cluster 11 (accessibility/equity — training data, disabilities, charging routines) and the social-context dimension of alerts (Q11). The equity/stakeholder framings carry through CG-14 and CG-15 as preserve-distinct. AA's 4 orphan questions (Q3, Q7, Q8, Q13) also need placement per B3.*

**Devil's Advocate (3 unique):** DA has 14 questions. Appearing in CGs: Q1→CG-13, Q2→CG-5, Q3→(no CG — unique; Liability for Missed Events is Cluster 9), Q4→CG-1, Q5→CG-16, Q6→CG-10, Q7→CG-11, Q8→CG-9, Q9→CG-3, Q10→CG-17, Q12→CG-14, Q14→(no CG — unique; Runway Reality Cluster 10). Not in CG: Q3 (liability for missed events), Q11 (wrist compliance challenge), Q13 (commodity pressure), Q14 (runway reality). **DA unique: 4 of 14 (Q3, Q11, Q13, Q14).**
*DA's high convergence (10 of 14) is consistent with Tier 1 structural critique role. Unique questions are DA-distinctive: Q3 (liability — Cluster 9 standalone), Q11 (wrist compliance — Cluster 5 human-systems risk), Q13 (competitive moat — Cluster 10 strategic), Q14 (runway reality — Cluster 10 execution risk).*

**Empath (5 unique):** Empath has 12 questions. Appearing in CGs: Q3→CG-14 (preserve-distinct), Q4→CG-3, Q9→CG-14, Q12→CG-8 (preserve-distinct). In B1 clusters alone: Q1, Q2, Q5, Q6, Q7, Q8, Q10, Q11. Of these, Q1, Q5, Q6 are in CG-15 (preserve-distinct); Q7 and Q10 are in Cluster 11 unique. Not in CG: Q2 (weight of knowing), Q7 (who signs up), Q8 (intimacy of breathing sounds), Q10 (targeting 40+), Q11 (gadget that signals something's wrong). **Empath unique: 5 of 12 (Q2, Q7, Q8, Q10, Q11).**
*Highest felt-experience framing in this cell. Unique questions extend beyond the CG-15 hyper-vigilance cluster to touch ethical framings (Q7 who signs up, Q10 targeting ethics), sensory-vulnerability framing (Q8 breathing intimacy), sustained-question framing (Q2 weight of knowing), existential framing (Q11 device designed to deliver bad news). Each addresses an emotional dimension no other persona captures — at high risk of being stripped by synthesis even where they are "unique" rather than "convergent."*

**FPT (1 unique):** FPT has 10 questions. Appearing in CGs: Q2→(touches CG-1/CG-3 privacy — orphan per B1), Q3→CG-18 (preserve-distinct), Q4→CG-16, Q5→CG-16, Q6→CG-9, Q7→CG-5, Q8→CG-18, Q9→CG-12, Q10→(touches CG-9 indirectly, Cluster 3 alone). Not in CG: Q1 (why a wearable at all). **FPT unique: 1 of 10 (Q1).**
*FPT contributes heavily to convergence (9 of 10) because reductive-analytical mode shares concern-space with Analyst, Questioner, TE, Systems Thinker. Q1 (form-factor-assumption reframing) is the one FPT standalone — distinctive because it challenges the most fundamental design assumption (that it's a wrist-worn wearable at all).*

**Futurist (4 unique):** Futurist has 12 questions. Appearing in CGs: Q1→CG-5, Q2→CG-7, Q4→CG-4, Q5→CG-3, Q6→CG-4, Q7→CG-10, Q8→CG-10, Q9→CG-17, Q10→CG-7, Q11→CG-7, Q12→CG-13. Not in CG: Q3 (wearable category evolution). **Futurist unique: 1 of 12 (Q3).**
*Futurist's 11 of 12 in convergence is the highest cross-persona integration rate in the cell. Each Futurist question's trend-grounding ("documented," "accelerating," "trajectory") is at risk of being stripped through merger into Analyst/Systems Thinker-style strategic questions. Cluster 10 (Q3 — category evolution) is the one Futurist standalone.*

**Lawyer (1 unique):** Lawyer has 10 questions. Appearing in CGs: Q1→CG-5, Q2→CG-6, Q3→CG-4, Q4→CG-1, Q5→(Cluster 9 standalone — no cross-persona CG within liability cluster), Q6→CG-4, Q7→(Cluster 9 standalone), Q8→(Cluster 9 standalone), Q9→(Cluster 9 standalone), Q10→CG-6. Not in CG: Q5, Q7, Q8, Q9 all in Cluster 9 but only Q7 cross-persona converges with DA Q3 in the liability-for-misses theme. Revising: **Lawyer unique: 3 of 10 (Q5 BAA, Q8 duty-to-warn, Q9 insurance).** Q7 (false-negative liability) couples with DA Q3 (liability for missed events) as a 2-way convergence worthy of a CG but not listed above — I did not number this above. Adding as CG-19 conceptually, but for B2 tabulation I'll count Q7 as unique-pair with DA Q3 rather than its own named CG. For this baseline, treat Lawyer unique = 4 of 10 with the Q7+DA Q3 pair treated as soft convergence rather than a full merger.
*Lawyer's Cluster 9 (liability) content is mostly intra-cluster and cross-persona only with DA Q3. Q5 (BAA structure), Q8 (duty to warn), Q9 (insurance) are Lawyer-standalone because no other persona addresses BAA/duty/insurance at this level of specificity.*

**Questioner (5 unique):** Questioner has 20 questions. Appearing in CGs: Q1→CG (data minimization — orphan-ish in CG-1 without explicit 5th seat), Q2→(no CG, orphan), Q3→CG-2, Q4→CG-2, Q5→(no CG — compelled disclosure is unique), Q6→(orphan — Cluster 8 unique), Q7→(orphan — Cluster 8 unique), Q8→CG-12, Q9→CG-10, Q10→CG-10, Q11→CG-5, Q12→CG-18, Q13→CG-13, Q14→(no CG — off-label use is unique), Q15→(no CG — regulatory sandbox is unique), Q16→CG-16, Q17→CG-9, Q18→CG-12, Q19→(no CG — manufacturing variability is unique), Q20→CG-11. Unique: Q2 (user control transparency), Q5 (compelled disclosure), Q14 (off-label use implications), Q15 (regulatory sandbox), Q19 (manufacturing variability). Soft-unique (Cluster 8 uniques): Q6, Q7. Also Q1 should be treated as within CG-1 — checking: CG-1 includes Analyst Q5, Analyst Q8, DA Q4, Lawyer Q4. Questioner Q1 (data minimization paradox) addresses the same concern — adding to CG-1 as 5th member would increase its density. For this baseline, I will treat Questioner Q1 as a soft-addition to CG-1 but not re-open the merge text. **Questioner unique: 7 of 20 (Q2, Q5, Q6, Q7, Q14, Q15, Q19).**
*Questioner's 20 questions land 13 in convergence and 7 unique — meta-question-generator pattern holding. Unique questions are Questioner-specific meta-questions (user control, compelled disclosure, off-label, regulatory sandbox, manufacturing variability) that no other persona approximates. Q2 (user control transparency) bridges Cluster 1 privacy and Cluster 4 alert agency; treated as orphan in B1.*

**Systems Thinker (4 unique):** ST has 12 questions. Appearing in CGs: Q1→CG-13, Q2→CG-15 (preserve-distinct), Q3→CG-15, Q4→CG or orphan → checking: ST Q4 (power-consumption detection spiral) is in Cluster 3 as part of CG-9 or standalone? CG-9 covers model architecture/NPU. Power-compute spiral reinforces loops spanning Cluster 3 + Cluster 7. Treating as part of Cluster 3 compute-power framing but not in named CG — unique archetype framing. Revising: ST Q4 unique. Q5→(orphan), Q6→CG-5, Q7→CG-10, Q8→CG-17, Q9→CG-18 (preserve-distinct), Q10→CG or Cluster 4 — ST Q10 (alert framing therapeutic expectation loop) is distinct from CG-13 and CG-14 — treat as unique cluster 4 framing. Q11→CG-12, Q12→(orphan — bidirectional loop). Revising: **ST unique: 4 of 12 (Q4 power-compute spiral, Q5 privacy-performance delayed feedback which is orphan, Q10 alert therapeutic expectation, Q12 companion-app bidirectional).**
*ST voice is load-bearing. Named archetypes (reinforcing cycles, Shifting the Burden, Success to the Successful, Fixes that Fail) appear across 9+ questions. Even where ST converges with other personas, merge text must preserve at least one named-archetype reference. Voice-stripping here would be catastrophic. Unique questions are ST-specific archetype instantiations that carry the "system-dynamic reasoning" voice independently.*

**TE (2 unique):** TE has 10 questions. Appearing in CGs: Q1→CG-9, Q2→CG-9, Q3→(Cluster 8 unique), Q4→CG-12, Q5→CG-12, Q6→(Cluster 6 unique — edge cases in continuous sensing; not in CG-12 explicitly because CG-12 focuses on fusion architecture not edge cases), Q7→CG-16, Q8→(Cluster 4 unique — deterministic inference latency for cardiac response), Q9→(Cluster 3 unique — fault tolerance and recovery), Q10→CG-2. **TE unique: 4 of 10 (Q3, Q6, Q8, Q9).**
*TE voice is engineering-specific (watchdog, CRC, worst-case latency, edge-case handling). Unique questions are precisely the TE-distinctive engineering concerns (on-device personalization within SRAM constraints, edge cases in sensing, deterministic latency, fault tolerance) that no other persona approximates. Q8 (<5 second cardiac response) and Q9 (safe mode behavior) are TE-standalone engineering concerns; Q3 (personalization within 128KB SRAM) bridges Cluster 3 and Cluster 8.*

---

## Convergence Density Notes for B3

- **~68% convergence is higher than all prior baselines (food-truck/high 64%, tool-library/high 62%, habit-tracker/high 59%).** Expected for a topic with 11 Synthesize personas across 3 Tier groups where the technical architecture (privacy, ML, sensors, power, alerts) is tightly coupled — multiple personas address the same architectural decisions from different lenses (Analyst analytical, TE engineering, DA critical, Lawyer regulatory, Futurist trend, FPT reductive). Wearable-device's technical-regulatory-emotional integration produces the densest convergence observed.

- **14 mergeable groups and 4 preserve-distinct groups** — preserve-distinct rate is ~22%, higher than food-truck/high (~19%) and comparable to habit-tracker/high (~39% in a smaller group count). The preserve-distinct groups are concentrated in (a) the user-experience/alert interpretation cluster (CG-14, CG-15), (b) the first-principles/validation cluster (CG-18), and (c) the stakeholder-interpretation cluster (CG-8). These are the cells where framing-distinctness matters most — the clinical-wellness user journey, the continuous-monitoring psychological burden, the alert agency/actionability distinctions, and the primitive-reframing concerns.

- **CG-5 (Wellness/Clinical Boundary) is the heaviest cross-persona merger at 8-way.** This is the largest single merger in any BL1 cell so far. Absorbs Analyst (×2), DA, Lawyer, Systems Thinker, FPT, Futurist, AI. Merge must preserve: (a) Analyst's analytical decomposition (migration pathway), (b) DA's critical framing (dual-path risk, users treating wellness as clinical), (c) Lawyer's regulatory specificity (boundary language, compliance-by-design), (d) ST's archetype framing (path dependency), (e) FPT's reductive framing (technical definitions of wellness vs clinical), (f) Futurist's trend-grounding (regulatory convergence window), (g) AI's strengths-based framing (regulatory success as enabler). Variants that produce a generic "navigate the wellness-to-clinical transition" fail SQ3 for 7 personas simultaneously.

- **CG-9 (Model Architecture/NPU) is 7-way across Analyst, DA, Questioner, TE, FPT** — also very dense. Merge must preserve: (a) TE's engineering specificity (INT8, sparse compute, zero-point quantization, asymmetric architectures), (b) DA's critical framing (compute-accuracy tradeoff, validation that power hasn't forced compromise), (c) Questioner's meta framing (NPU utilization thermal limits), (d) FPT's reductive framing (matrix multiplication as bottleneck question, traditional ML alternatives). Variants that strip any of these fail SQ3 for the corresponding persona.

- **CG-10 (Model Updates/Drift/Personalization) is 7-way** — another heavy merger. Preservation needs: Analyst framework, DA drift concerns, Questioner personalization-update strategy, ST archetype (sync-asynchrony), Futurist trajectory (edge ML, federated learning).

- **AI has 67% unique rate (8 of 12)** — 5 more AI questions than food-truck where AI was 100% unique. Wearable-device/high has some cross-persona convergence involving AI (Q2 in CG-3, Q6 in CG-5, Q8 in CG-3, Q10 in CG-7) but 8 questions remain standalone. AI's appreciative-framing contribution to Cluster 5 (Q1, Q3, Q4), Cluster 4 (Q5), Cluster 7 (Q9), Cluster 10 (Q7, Q11, Q12) is all standalone and load-bearing.

- **Empath has 5 of 12 unique and 3 in preserve-distinct CG-15 and 1 in preserve-distinct CG-14.** Total voice-preservation dependencies: 9 of 12 questions carry Empath-distinctive framing that must survive either as unique or as preserve-distinct group member. Critical risk: synthesis strips felt-experience language and reduces to neutral design questions.

- **Futurist has 11 of 12 in convergence** — highest convergence rate. Trend-grounding vocabulary is the risk: if merged text strips "documented," "accelerating," "trajectory," Futurist voice becomes indistinguishable from Analyst/Systems Thinker strategic questions.

- **Accountant is absent** (this cell has Lawyer + TE + Connector as Tier 3, not Accountant). Unlike food-truck/high and tool-library/high, voice-preservation concerns are not Accountant-anchored here.

- **Variants merging any of the 4 preserve-distinct groups (CG-8, CG-14, CG-15, CG-18) over-merge.** Variants failing to merge ~11+ of the 14 mergeable groups under-utilize convergence. Variants producing good merges on CG-1, CG-3, CG-5, CG-9, CG-10, CG-12, CG-13, CG-16 (the largest mergers, 4+ personas each) demonstrate the core synthesis task was executed correctly.

- **GT1 watchlist reminder:** This cell is **NOT on the GT1 medium-confidence watchlist.** Tier 3 Synthesize composition (Lawyer + TE) and Connector Append swap are high-confidence. Convergence counts above are canonical for GT1 Rev 3.
